A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily function.

Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s disease, a step that could pave the way for new treatments for the condition.

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon ’s experimental therapy preserved the hippocampus, a brain structure ...

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk by measuring levels of certain forms of the amyloid beta protein, a known ...

On-demand treatment with BXCL501 was found to significantly ease episodes of agitation for Alzheimer's patients in a Phase 3 clinical trial.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.

The FDA approved Rexulti (brexpiprazole) as the first therapy in the U.S. for agitation associated with dementia due to Alzheimer’s disease.

Nearly half the Alzheimer's disease patients treated with TrueBinding's investigational therapy TB006 showed cognitive improvement signs.